{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:12:52Z","timestamp":1740107572238,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","award":["not applicable"],"award-info":[{"award-number":["not applicable"]}],"id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pfizer Oncology","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>External quality assessment (EQA) schemes assess the performance of predictive biomarker testing in lung and colorectal cancer and have previously demonstrated variable error rates. No information is currently available on the underlying causes of incorrect EQA results in the laboratories. Participants in EQA schemes by the European Society of Pathology between 2014 and 2018 for lung and colorectal cancer were contacted to complete a survey if they had at least one analysis error or test failure in the provided cases. Of the 791 surveys that were sent, 325 were completed including data from 185 unique laboratories on 514 incorrectly analyzed or failed cases. For the digital cases and immunohistochemistry, the majority of errors were interpretation-related. For fluorescence in situ hybridization, problems with the EQA materials were reported frequently. For variant analysis, the causes were mainly methodological for lung cancer but variable for colorectal cancer. Post-analytical (clerical and interpretation) errors were more likely detected after release of the EQA results compared to pre-analytical and analytical issues. Accredited laboratories encountered fewer reagent problems and more often responded to the survey. A recent change in test methodology resulted in method-related problems. Testing more samples annually introduced personnel errors and lead to a lower performance in future schemes. Participation to quality improvement projects is important to reduce deviating test results in laboratories, as the different error causes differently affect the test performance. EQA providers could benefit from requesting root cause analyses behind errors to offer even more tailored feedback, subschemes, and cases.<\/jats:p>","DOI":"10.1007\/s00428-020-02966-7","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T04:26:00Z","timestamp":1606105560000},"page":"995-1006","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Causes behind error rates for predictive biomarker testing: the utility of sending post-EQA surveys"],"prefix":"10.1007","volume":"478","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4498-8386","authenticated-orcid":false,"given":"Cleo","family":"Keppens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3655-143X","authenticated-orcid":false,"given":"Ed","family":"Schuuring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth M. C.","family":"Dequeker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,23]]},"reference":[{"issue":"7","key":"2966_CR1","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1097\/JTO.0b013e318290868f","volume":"8","author":"NI Lindeman","year":"2013","unstructured":"Lindeman NI, Cagle PT, Beasley M et al (2013) Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 8(7):823\u2013859. https:\/\/doi.org\/10.1097\/JTO.0b013e318290868f","journal-title":"J Thorac Oncol"},{"issue":"2","key":"2966_CR2","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jmoldx.2017.11.004","volume":"20","author":"NI Lindeman","year":"2018","unstructured":"Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, Colasacco C, Dacic S, Hirsch FR, Kerr K, Kwiatkowski DJ, Ladanyi M, Nowak JA, Sholl L, Temple-Smolkin R, Solomon B, Souter LH, Thunnissen E, Tsao MS, Ventura CB, Wynes MW, Yatabe Y (2018) Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Mol Diagn 20(2):129\u2013159. https:\/\/doi.org\/10.1016\/j.jmoldx.2017.11.004","journal-title":"J Mol Diagn"},{"issue":"11","key":"2966_CR3","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1136\/jclinpath-2014-202404","volume":"67","author":"IA Cree","year":"2014","unstructured":"Cree IA, Deans ZC, Ligtenberg MJL, Normanno N, Edsj\u00f6 A, Rouleau E, Sol\u00e9 F, Thunnissen E, Timens W, Schuuring E, Dequeker E, Murray S, Dietel M, Groenen P, van Krieken J, European Society of Pathology Task Force on Quality Assurance in Molecular Pathology., Royal College of Pathologists (2014) Guidance for laboratories performing molecular pathology for cancer patients. J Clin Pathol 67(11):923\u2013931. https:\/\/doi.org\/10.1136\/jclinpath-2014-202404","journal-title":"J Clin Pathol"},{"issue":"2","key":"2966_CR4","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/bjc.2014.353","volume":"111","author":"S Patton","year":"2014","unstructured":"Patton S, Normanno N, Blackhall F, Murray S, Kerr KM, Dietel M, Filipits M, Benlloch S, Popat S, Stahel R, Thunnissen E (2014) Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing. Br J Cancer 111(2):413\u2013420. https:\/\/doi.org\/10.1038\/bjc.2014.353","journal-title":"Br J Cancer"},{"issue":"2","key":"2966_CR5","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jmoldx.2015.09.004","volume":"18","author":"EMC Dequeker","year":"2016","unstructured":"Dequeker EMC, Keppens C, Egele C, Delen S, Lamy A, Lemoine A, Sabourin JC, Andrieu C, Ligtenberg M, Fetique D, Tops B, Descarpentries C, Blons H, Denoux Y, Aube C, Penault-Llorca F, Hofman P, Leroy K, le Marechal C, Doucet L, Duranton-Tanneur V, Pedeutour F, Soubeyran I, C\u00f4t\u00e9 JF, Emile JF, Vignaud JM, Monhoven N, Haddad V, Laurent-Puig P, van Krieken H, Nowak F, Lonchamp E, Bellocq JP, Rouleau E (2016) Three rounds of external quality assessment in France to evaluate the performance of 28 platforms for multiparametric molecular testing in metastatic colorectal and non-small cell lung cancer. J Mol Diagn 18(2):205\u2013214. https:\/\/doi.org\/10.1016\/j.jmoldx.2015.09.004","journal-title":"J Mol Diagn"},{"issue":"2","key":"2966_CR6","doi-asserted-by":"publisher","first-page":"e000160","DOI":"10.1136\/esmoopen-2017-000160","volume":"2","author":"N Normanno","year":"2017","unstructured":"Normanno N, Fenizia F, Castiglione F, Barberis M, Taddei GL, Truini M, De Rosa G, Pinto C, Marchetti A (2017) External quality assessment for EGFR mutations in Italy: improvements in performances over the time. ESMO Open 2(2):e000160. https:\/\/doi.org\/10.1136\/esmoopen-2017-000160","journal-title":"ESMO Open"},{"issue":"6","key":"2966_CR7","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00428-017-2162-7","volume":"471","author":"SD Richman","year":"2017","unstructured":"Richman SD, Fairley J, Butler R, Deans ZC (2017) RAS screening in colorectal cancer: a comprehensive analysis of the results from the UK NEQAS colorectal cancer external quality assurance schemes (2009-2016). Virchows Arch 471(6):721\u2013729. https:\/\/doi.org\/10.1007\/s00428-017-2162-7","journal-title":"Virchows Arch"},{"key":"2966_CR8","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s12967-015-0655-1","volume":"13","author":"N Normanno","year":"2015","unstructured":"Normanno N, Pinto C, Castiglione F, Fenizia F, Barberis M, Marchetti A, Fontanini G, De Rosa G, Taddei GL (2015) The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences. J Transl Med 13:287. https:\/\/doi.org\/10.1186\/s12967-015-0655-1","journal-title":"J Transl Med"},{"issue":"10","key":"2966_CR9","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1097\/JTO.0000000000000280","volume":"9","author":"A Marchetti","year":"2014","unstructured":"Marchetti A, Barberis M, Papotti M, Rossi G, Franco R, Malatesta S, Buttitta F, Ardizzoni A, Crin\u00f2 L, Gridelli C, Taddei GL, Clemente C, Scagliotti G, Normanno N, Pinto C (2014) ALK rearrangement testing by FISH analysis in non-small-cell lung cancer patients: results of the first italian external quality assurance scheme. J Thorac Oncol 9(10):1470\u20131476. https:\/\/doi.org\/10.1097\/JTO.0000000000000280","journal-title":"J Thorac Oncol"},{"issue":"4","key":"2966_CR10","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1136\/jclinpath-2012-201227","volume":"66","author":"ZC Deans","year":"2013","unstructured":"Deans ZC, Bilbe N, O'Sullivan B, Lazarou LP, de Castro DG, Parry S, Dodson A, Taniere P, Clark C, Butler R (2013) Improvement in the quality of molecular analysis of EGFR in non-small-cell lung cancer detected by three rounds of external quality assessment. J Clin Pathol 66(4):319\u2013325. https:\/\/doi.org\/10.1136\/jclinpath-2012-201227","journal-title":"J Clin Pathol"},{"issue":"9","key":"2966_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2217\/crc-2019-0013","volume":"1","author":"K Dufraing","year":"2020","unstructured":"Dufraing K, Keppens C, Tack V, Siebers AG, Kafatos G, Dube S, Demonty G, Lowe K, Kroeze LI, Ligtenberg MJL, Normanno N, Tembuyser L, Sara VB, van Krieken JH, C Dequeker EM (2020) Evolution of RAS testing over time: factors influencing mutation rates in metastatic colorectal cancer patients. Colorect Cancer 1(9):1\u201317. https:\/\/doi.org\/10.2217\/crc-2019-0013","journal-title":"Colorect Cancer"},{"issue":"29","key":"2966_CR12","doi-asserted-by":"publisher","first-page":"20524","DOI":"10.18632\/oncotarget.24980","volume":"9","author":"C Keppens","year":"2018","unstructured":"Keppens C, Tack V, \u2018t Hart N et al (2018) A stitch in time saves nine: external quality assessment rounds demonstrate improved quality of biomarker analysis in lung cancer. Oncotarget 9(29):20524\u201320538. https:\/\/doi.org\/10.18632\/oncotarget.24980","journal-title":"Oncotarget"},{"issue":"1","key":"2966_CR13","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1186\/s12885-020-06831-3","volume":"20","author":"C Keppens","year":"2020","unstructured":"Keppens C, Dequeker EMC, Rouleau E, \u2019t Hart N, Bubendorf L, Dufraing K, Garrec C, Gu\u00e9guen P, Lamy A, Marchetti A, Pauwels P, Ryska A, Tack V, Tornillo L, van Casteren K, von der Th\u00fcsen JH, Zwaenepoel K, Lissenberg-Witte B, Thunnissen E, Schuuring E (2020) Sensitive detection methods are key to identify secondary EGFR c.2369C>T p.(Thr790Met) in non-small cell lung cancer tissue samples. BMC Cancer 20(1):366. https:\/\/doi.org\/10.1186\/s12885-020-06831-3","journal-title":"BMC Cancer"},{"issue":"5","key":"2966_CR14","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41416-018-0204-9","volume":"119","author":"V Tack","year":"2018","unstructured":"Tack V, Schuuring E, Keppens C, \u2018t Hart N, Pauwels P, van Krieken H, Dequeker EMC (2018) Accreditation, setting and experience as indicators to assure quality in oncology biomarker testing laboratories. Br J Cancer 119(5):605\u2013614. https:\/\/doi.org\/10.1038\/s41416-018-0204-9","journal-title":"Br J Cancer"},{"key":"2966_CR15","volume-title":"ISO 15189:2012 medical laboratories\u2014particular requirements for quality and competence","author":"International Organization for Standardization (ISO)","year":"2012","unstructured":"International Organization for Standardization (ISO) (2012) ISO 15189:2012 medical laboratories\u2014particular requirements for quality and competence. ISO, Geneva"},{"key":"2966_CR16","unstructured":"Clinical Laboratory Improvement Amendments of 1988, 42 U.S.C. 263a PL100-578 (1988) Laboratory requirements, 2003, 42 C.F.R. Chapter IV, Part 493"},{"key":"2966_CR17","volume-title":"ISO 17043:2010 conformity assessment - general requirements for proficiency testing","author":"International Organization for Standardization (ISO)","year":"2010","unstructured":"International Organization for Standardization (ISO) (2010) ISO 17043:2010 conformity assessment - general requirements for proficiency testing. ISO, Geneva"},{"issue":"1","key":"2966_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00428-012-1354-4","volume":"462","author":"JH van Krieken","year":"2013","unstructured":"van Krieken JH, Normanno N, Blackhall F, Boone E, Botti G, Carneiro F, Celik I, Ciardiello F, Cree IA, Deans ZC, Edsj\u00f6 A, Groenen PJTA, Kamarainen O, Kreipe HH, Ligtenberg MJL, Marchetti A, Murray S, Opdam FJM, Patterson SD, Patton S, Pinto C, Rouleau E, Schuuring E, Sterck S, Taron M, Tejpar S, Timens W, Thunnissen E, van de Ven PM, Siebers AG, Dequeker E (2013) Guideline on the requirements of external quality assessment programs in molecular pathology. Virchows Arch 462(1):27\u201337. https:\/\/doi.org\/10.1007\/s00428-012-1354-4","journal-title":"Virchows Arch"},{"key":"2966_CR19","doi-asserted-by":"publisher","unstructured":"Dufraing K, Fenizia F, Torlakovic E, Wolstenholme N, Deans ZC, Rouleau E, Vyberg M, Parry S, Schuuring E, Dequeker E, on behalf of IQNPath ABSL (2020) Biomarker testing in oncology \u2013 requirements for organizing external quality assessment programs to improve the performance of laboratory testing: revision of an expert opinion paper on behalf of IQNPath ABSL. Virchows Arch:1\u201313. https:\/\/doi.org\/10.1007\/s00428-020-02928-z","DOI":"10.1007\/s00428-020-02928-z"},{"issue":"2","key":"2966_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1309\/LM6ER9WJR1IHQAUY","volume":"43","author":"A Hammerling","year":"2012","unstructured":"Hammerling A (2012) Review of medical errors in laboratory diagnostics and where we are today. Lab Med 43(2):41\u201344. https:\/\/doi.org\/10.1309\/LM6ER9WJR1IHQAUY","journal-title":"Lab Med"},{"key":"2966_CR21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.fsigen.2014.04.014","volume":"12","author":"A Kloosterman","year":"2014","unstructured":"Kloosterman A, Sjerps M, Quak A (2014) Error rates in forensic DNA analysis: definition, numbers, impact and communication. Forensic Sci Int Genet 12:77\u201385. https:\/\/doi.org\/10.1016\/j.fsigen.2014.04.014","journal-title":"Forensic Sci Int Genet"},{"issue":"1","key":"2966_CR22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.11613\/BM.2017.007","volume":"27","author":"GB Kristensen","year":"2017","unstructured":"Kristensen GB, Meijer P (2017) Interpretation of EQA results and EQA-based trouble shooting. Biochem Med 27(1):49\u201362. https:\/\/doi.org\/10.11613\/BM.2017.007","journal-title":"Biochem Med"},{"issue":"10","key":"2966_CR23","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1515\/cclm-2017-1179","volume":"56","author":"L Sciacovelli","year":"2018","unstructured":"Sciacovelli L, Secchiero S, Padoan A, Plebani M (2018) External quality assessment programs in the context of ISO 15189 accreditation. Clin Chem Lab Med 56(10):1644\u20131654. https:\/\/doi.org\/10.1515\/cclm-2017-1179","journal-title":"Clin Chem Lab Med"},{"issue":"10","key":"2966_CR24","doi-asserted-by":"publisher","first-page":"E837","DOI":"10.3390\/diagnostics10100837","volume":"10","author":"C Keppens","year":"2020","unstructured":"Keppens C, Schuuring E, Dequeker EM (2020) Managing deviating EQA results: a survey to assess the corrective and preventive actions of medical laboratories testing for oncological biomarkers. Diagnostics (Basel) 10(10):E837. https:\/\/doi.org\/10.3390\/diagnostics10100837","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"2966_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00428-019-02525-9","volume":"475","author":"C Keppens","year":"2019","unstructured":"Keppens C, Dufraing K, van Krieken HJ, Siebers AG, Kafatos G, Lowe K, Demonty G, Dequeker EMC (2019) European follow-up of incorrect biomarker results for colorectal cancer demonstrates the importance of quality improvement projects. Virchows Arch 475(1):25\u201337. https:\/\/doi.org\/10.1007\/s00428-019-02525-9","journal-title":"Virchows Arch"},{"issue":"34","key":"2966_CR26","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/JCO.2017.74.7642","volume":"35","author":"R B\u00fcttner","year":"2017","unstructured":"B\u00fcttner R, Gosney JR, Skov BG, Adam J, Motoi N, Bloom KJ, Dietel M, Longshore JW, L\u00f3pez-R\u00edos F, Penault-Llorca F, Viale G, Wotherspoon AC, Kerr KM, Tsao MS (2017) Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non-small-cell lung cancer. J Clin Oncol 35(34):3867\u20133876. https:\/\/doi.org\/10.1200\/JCO.2017.74.7642","journal-title":"J Clin Oncol"},{"issue":"4","key":"2966_CR27","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.jmoldx.2018.03.003","volume":"20","author":"K Dufraing","year":"2018","unstructured":"Dufraing K, De Hertogh G, Tack V, Keppens C, Dequeker EMC, van Krieken JH (2018) External quality assessment identifies training needs to determine the neoplastic cell content for biomarker testing. J Mol Diagn 20(4):455\u2013464. https:\/\/doi.org\/10.1016\/j.jmoldx.2018.03.003","journal-title":"J Mol Diagn"},{"key":"2966_CR28","doi-asserted-by":"publisher","first-page":"30482","DOI":"10.1016\/j.jmoldx.2020.09.006","volume":"20","author":"C Keppens","year":"2020","unstructured":"Keppens C, von der Th\u00fcsen JH, Pauwels P, Ryska A, \u2018t Hart N, Schuuring E, Miller K, Thunnissen E, Zwaenepoel K, Dequeker EMC (2020) Staining performance of ALK and ROS1 immunohistochemistry and influence on molecular interpretation in NSCLC. J Mol Diagn 20:30482\u201330487. https:\/\/doi.org\/10.1016\/j.jmoldx.2020.09.006","journal-title":"J Mol Diagn"},{"issue":"2","key":"2966_CR29","doi-asserted-by":"publisher","first-page":"140","DOI":"10.5858\/arpa.2011-0206-CP","volume":"136","author":"BA Jones","year":"2012","unstructured":"Jones BA, Darcy T, Souers RJ, Meier FA (2012) Staffing benchmarks for clinical laboratories: a College of American Pathologists Q-Probes study of laboratory staffing at 98 institutions. Arch Pathol Lab Med 136(2):140\u2013147. https:\/\/doi.org\/10.5858\/arpa.2011-0206-CP","journal-title":"Arch Pathol Lab Med"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-020-02966-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-020-02966-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-020-02966-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T22:09:23Z","timestamp":1620252563000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-020-02966-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,23]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["2966"],"URL":"https:\/\/doi.org\/10.1007\/s00428-020-02966-7","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"type":"print","value":"0945-6317"},{"type":"electronic","value":"1432-2307"}],"subject":[],"published":{"date-parts":[[2020,11,23]]},"assertion":[{"value":"19 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"CK and EMCD have nothing to declare. ES received honoraria for consultancy\/advisory board from AstraZeneca, MSD\/Merck, Roche, Pfizer, Bayer, Novartis, BMS, BioRad, Illumina, Ageno BioSciences, Janssen Cilag (Johnson&Johnson), and BioCartis; speaker\u2019s fee from AstraZeneca, Ageno BioSciences, Roche, Pfizer, Novartis, BioRad, Illumina, and BioCartis; and (unrestricted) grants from Boehringer Ingelheim, BMS, Biocartis, BioRad, Ageno BioSciences, and Roche (all outside the submitted work and fees to UMCG).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The samples originated from tissue blocks of leftover patient material obtained during routine care. Each scheme organizer signed a subcontractor agreement stating that the way in which the samples were obtained conformed to the national legal requirements for the use of patient samples. The samples were excluded from research regulations requiring informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}